Retatrutide 10 mg

Retatrutide is an advanced investigational peptide designed as a triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). By engaging these three metabolic pathways simultaneously, Retatrutide produces a coordinated effect on appetite regulation, energy balance, and glucose homeostasis.

Through GLP-1 and GIP receptor activation, Retatrutide enhances satiety, reduces caloric intake, and supports glucose-dependent insulin signaling. Concurrent activation of the glucagon receptor promotes lipid mobilization and increases overall energy expenditure. This integrated mechanism allows Retatrutide to influence body weight, glycemic control, and lipid metabolism more broadly than single- or dual-receptor agonists.

(Frías et al., 2023 — New England Journal of Medicine).

Retatrutide has also demonstrated favorable effects on cardiometabolic parameters, including fasting glucose, HbA1c, blood pressure, triglycerides, and cholesterol profiles. In metabolic-associated fatty liver disease research, substantial reductions in hepatic fat content have been observed, highlighting its potential relevance in liver-related metabolic disorders.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.